

Here for you from the start

With 10+ years of clinical trial
experience in achondroplasia

Sophie

9 MONTHS OLD
on VOXZOGO since
3 months old

VOXZOGO[®]
(vosoritide) for injection

The first and only treatment FDA
approved for children with achondroplasia
from birth until growth plates close.

INDICATION AND IMPORTANT SAFETY INFORMATION

- VOXZOGO[®] (vosoritide) is a prescription medicine used to increase linear growth in children with achondroplasia and open growth plates (epiphyses).
- VOXZOGO is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

What is the most important safety information about VOXZOGO?


- VOXZOGO may cause serious side effects including a temporary decrease in blood pressure in some patients. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, feeling tired, or nausea), patients should eat a meal and drink 8 to 10 ounces of fluid within 1 hour before receiving VOXZOGO.

Please see Important Safety Information throughout, as well as the full [Prescribing Information](#) and [Patient Information](#).

Bones only grow for a limited time


Bones mainly develop from cartilage (called **endochondral bones**) and they only grow for a limited time—from before birth until late adolescence or early adulthood.

The most rapid growth occurs in the first 2 years of life.



Endochondral bone growth is inhibited in achondroplasia, affecting over 90% of the body's bones.

This is caused by an imbalance of cell signals, which impacts physical development throughout the body.



- Endochondral bones
- Growth plates

This simplified image is for illustrative purposes only.



See the impact of inhibited bone growth in achondroplasia

Please see Important Safety Information throughout, as well as the full [Prescribing Information](#) and [Patient Information](#).

VOXZOGO supports bone growth as early as birth

VOXZOGO is a once-daily injection for infants and children that **targets the cause of achondroplasia by mimicking the body's natural cell signals** to help increase linear growth.*



Corinna

20 MONTHS OLD
on VOXZOGO since
8 months old as part
of a clinical trial

VOXZOGO[®]
(vosoritide) for injection

*Linear growth, an increase in height, is an indicator of overall health and development.

IMPORTANT SAFETY INFORMATION


What are the most common side effects of VOXZOGO?

- The most common side effects of VOXZOGO include injection site reactions (including redness, itching, swelling, bruising, rash, hives, and injection site pain), high levels of blood alkaline phosphatase shown in blood tests, vomiting, joint pain, decreased blood pressure, and stomach ache. These are not all the possible side effects of VOXZOGO. Ask your healthcare provider for medical advice about side effects, and about any side effects that bother the patient or that do not go away.

Children with achondroplasia can grow faster on VOXZOGO than without treatment

In a clinical trial of children aged 5 to 15 years, the impact of VOXZOGO on linear growth was measured over 1 year.

Growth rate before and after 1 year of treatment



Improvement in linear growth over baseline (from when treatment was started) was **maintained over 4 years** in an ongoing study.

At year 4, the rate of growth was **1.88 in/yr.[†]**

97% of children (58/60) stayed on VOXZOGO during the first year.[‡]

*The difference when accounting for group characteristics, including sex and Tanner stage, treatment, baseline age, baseline growth rate, and baseline height Z-score.

[†]These results are from the long-term follow-up study of the same clinical trial (known as an open-label extension), which did not have a placebo group, and caregivers, patients, and doctors were aware that all children were given VOXZOGO.

[‡]One child discontinued due to injection pain, and one child discontinued due to fear of needles.

IMPORTANT SAFETY INFORMATION

How is VOXZOGO taken?

- VOXZOGO is taken daily as an injection given under the skin, administered by a caregiver after a healthcare provider determines the caregiver is able to administer VOXZOGO. Do not try to inject VOXZOGO until you have been shown the right way by your healthcare provider. VOXZOGO is supplied with Instructions for Use that describe the steps for preparing, injecting, and disposing VOXZOGO. Caregivers should review the Instructions for Use for guidance and any time they receive a refill of VOXZOGO in case any changes have been made.

Get to know the families who chose VOXZOGO

Annika

14 YEARS OLD

Started VOXZOGO: 9 years old as part of a clinical trial



Annika, 6 years old



Annika, 14 years old

For illustrative purposes only, image scale is not matched.



Hear families like Annika's share their stories during an educational webinar

Please see Important Safety Information throughout, as well as the full [Prescribing Information](#) and [Patient Information](#).

VOXZOGO[®]
(vosoritide) for injection

Understanding the safety of VOXZOGO over time

Below are the most common side effects seen in over 10% of children (aged 5 to 15 years) on VOXZOGO over 1 year in a clinical trial.*

SIDE EFFECT	PLACEBO (n=61)	VOXZOGO (n=60)
Injection site reddening (erythema) [†]	42 (69%)	45 (75%)
Injection site swelling [†]	22 (36%)	37 (62%)
Vomiting	12 (20%)	16 (27%)
Injection site hives (urticaria) [†]	6 (10%)	15 (25%)
Joint pain (arthralgia)	4 (7%)	9 (15%)
Decreased blood pressure	3 (5%)	8 (13%)
Stomach ache (gastroenteritis) [‡]	5 (8%)	8 (13%)

In ongoing studies of VOXZOGO, the side effects observed for up to 6 years of treatment are similar to those seen in the first year.

The safety of VOXZOGO in children 4 months to under 5 years old was similar to that seen in children ages 5 years and older.

Over 1 year, the most common side effects seen in over 10% of children on VOXZOGO (under 5 years old) were injection site reactions (86%) and rash (28%). In ongoing studies of VOXZOGO, the side effects observed for up to 4 years of treatment are similar to those seen in the first year.



It's important to know that VOXZOGO may cause serious side effects including a temporary decrease in blood pressure in some patients. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, feeling tired, or nausea), patients should eat a meal and drink 8 to 10 ounces of fluid within 1 hour before receiving VOXZOGO.

*Includes adverse reactions occurring in over 10% of VOXZOGO patients and more frequently in the VOXZOGO arm with a risk difference of $\geq 5\%$ (ie, difference of >2 subjects) between treatment arms.

[†]Injection site reactions occurring more frequently in VOXZOGO-treated subjects than placebo.

[‡]Includes the preferred terms: gastroenteritis and gastroenteritis, viral.



Sophie

9 MONTHS OLD
on VOXZOGO since
3 months old

Widespread coverage to help you get started



OVER 96% of insured patients have secured coverage for VOXZOGO*



OVER 96% of eligible families with commercial insurance paid \$0 out of pocket for VOXZOGO**

*BioMarin RareConnections™ Data on file. Patients included are eligible VOXZOGO patients who have enrolled in BioMarin RareConnections and are on commercial therapy.

**With the BioMarin Co-Pay Assistance Program. Terms and Conditions apply. Valid only for patients with commercial prescription insurance coverage who have a valid prescription for an FDA-approved indication and who meet additional eligibility criteria. Not valid for prescriptions reimbursed, in whole or in part, by any federal, state, or government-funded insurance programs (for example, Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, or TRICARE) or where prohibited by law or by the patient's health insurance provider. If at any time a patient begins receiving prescription drug coverage under any federal, state, or government funded healthcare program, the patient will no longer be able to use the program and patient must notify BioMarin RareConnections at 1-866-906-6100 to stop participation. Patients residing in or receiving treatment in certain states may not be eligible for some or all of the program elements. Patients may not seek reimbursement for value received from the program from any third-party payers. Additional restrictions may apply. Offer subject to change or discontinuance without notice. This assistance offer is not health insurance. See BioMarin-copay-terms.com for full Terms and Conditions.

Please see Important Safety Information throughout, as well as the full [Prescribing Information](#) and [Patient Information](#).

VOXZOGO
(vosoritide) for injection

Support and resources for every step of the way



BioMarin Clinical Coordinators

One-to-one support for you and your family

- Providing product education and support around the injection process
- Helping to find an injection routine that works for your family throughout your child's entire time on treatment
- Assisting through the specialty pharmacy process and sharing reminders for product refills
- Offering flexible meeting options including in person and/or virtually, by email, phone, or text



Shawn

8 YEARS OLD

on VOXZOGO since
4 years old as part
of a clinical trial



BioMarin RareConnections™

Case and Field Reimbursement Managers help navigate coverage by:

- Helping with the insurance process, sharing coverage options, and identifying financial programs
- Offering guidance on insurance changes
- Ensuring the specialty pharmacy receives your prescription
- Educating your doctor on coverage requirements for continued access to therapy

Important Safety Information

What is VOXZOGO used for?

- VOXZOGO is a prescription medicine used to increase linear growth in children with achondroplasia and open growth plates (epiphyses).
- VOXZOGO is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

What is the most important safety information about VOXZOGO?

- VOXZOGO may cause serious side effects including a temporary decrease in blood pressure in some patients. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, feeling tired, or nausea), patients should eat a meal and drink 8 to 10 ounces of fluid within 1 hour before receiving VOXZOGO.

What are the most common side effects of VOXZOGO?

- The most common side effects of VOXZOGO include injection site reactions (including redness, itching, swelling, bruising, rash, hives, and injection site pain), high levels of blood alkaline phosphatase shown in blood tests, vomiting, joint pain, decreased blood pressure, and stomach ache. These are not all the possible side effects of VOXZOGO. Ask your healthcare provider for medical advice about side effects, and about any side effects that bother the patient or that do not go away.

How is VOXZOGO taken?

- VOXZOGO is taken daily as an injection given under the skin, administered by a caregiver after a healthcare provider determines the caregiver is able to administer VOXZOGO. Do not try to inject VOXZOGO until you have been shown the right way by your healthcare provider. VOXZOGO is supplied with Instructions for Use that describe the steps for preparing, injecting, and disposing VOXZOGO. Caregivers should review the Instructions for Use for guidance and any time

they receive a refill of VOXZOGO in case any changes have been made.

- Inject VOXZOGO 1 time every day, at about the same time each day. If a dose of VOXZOGO is missed, it can be given within 12 hours from the missed dose. After 12 hours, skip the missed dose and administer the next daily dose as usual.
- The dose of VOXZOGO is based on body weight. Your healthcare provider will adjust the dose based on changes in weight following regular check-ups.
- Your healthcare provider will monitor the patient's growth and tell you when to stop taking VOXZOGO if they determine the patient is no longer able to grow. Stop administering VOXZOGO if instructed by your healthcare provider.

What should you tell the doctor before or during taking VOXZOGO?

- Tell your doctor about all of the patient's medical conditions including
 - If the patient has heart disease (cardiac or vascular disease), or if the patient is on blood pressure medicine (anti-hypertensive medicine).
 - If the patient has kidney problems or renal impairment.
 - If the patient is pregnant or plans to become pregnant. It is not known if VOXZOGO will harm the unborn baby.
 - If the patient is breastfeeding or plans to breastfeed. It is not known if VOXZOGO passes into breast milk.
- Tell your doctor about all of the medicines the patient takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to BioMarin at **1-866-906-6100**. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call **1-800-FDA-1088**.

Please see additional safety information in the full [Prescribing Information](#) and [Patient Information](#).

Chosen by [5,000+] families across the world

Join the thousands of families who have felt confident that VOXZOGO was the right choice for their infants and children with achondroplasia.

Together, they are discovering the impact of the first and only treatment FDA approved from birth.

Vihaan

7 YEARS OLD

on VOXZOGO since 5½ years old as part of a clinical trial



Connect with your local representative

To learn more about VOXZOGO, scan the QR code or go to VOXZOGO.com/Connect

VOXZOGO[®]
(vosoritide) for injection

IMPORTANT SAFETY INFORMATION

What is the most important safety information about VOXZOGO?

- VOXZOGO may cause serious side effects including a temporary decrease in blood pressure in some patients. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, feeling tired, or nausea), patients should eat a meal and drink 8 to 10 ounces of fluid within 1 hour before receiving VOXZOGO.

Please see Important Safety Information throughout, as well as the full [Prescribing Information](#) and [Patient Information](#).

B:OMARIN[®]

© 2026 BioMarin Pharmaceutical Inc. All rights reserved. COM-SC-1291 04/26